title: Feasibility of quantitative parameters of dynamically enhanced patterns of spiral computed tomography scanning integrated into tumour progression before targeted treatment of non-small cell lung cancer.
abstract: BACKGROUND
  The relationship between quantitative parameters of contrast-enhanced computed tomography (CT) and non-small cell lung cancer (NSCLC) progression remains controversial. We aimed to explore the usefulness of contrast-enhanced spiral CT scanning for confirming the time of tumour progression before targeted treatment of NSCLC.
  
  
  METHODS
  Contrast-enhanced spiral CT scanning was performed on 33 NSCLC patients with a biopsy-proven diagnosis of NSCLC. All the patients were divided into three groups according to times of tumour progression (<6 weeks, 6-20 weeks, and >20 weeks). The perfusion CT data were used to calculate quantitative parameters, including enhanced peak values, peak time of tumour enhancement, ratio of tumour mass and enhanced aorta peak value and perfusion value of blood flow. Variance analysis was used for statistical analysis among the three groups using SAS 9.13 statistical software.
  
  
  RESULTS
  Tumour perfusion values among the three group with different stage of TTP were significantly different from each other with P = 0.0129 (<6 weeks, perfusion value = 0.35 ± 0.15 mL/(min × mL); 6-20 weeks, perfusion value = 0.41 ± 0.086 mL/(min × mL); > 20 weeks, perfusion value = 0.47 ± 0.087 mL/(min × mL)). However, no significant differences were found in other parameters (enhanced peak values, peak time of tumour enhancement, ratios of tumour mass, and enhanced aorta peak value) among three groups (P > 0.05).
  
  
  CONCLUSIONS
  The NSCLC patients with high perfusion value before targeted therapy are more sensitive to targeted therapy, and further experiments with larger sample size are needed.
authors.affiliation: Department of Radiology, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, China.
authors.forename: Peng-Gang
authors.initials: PG
authors.lastname: Qiao
authors.forename: Qiong
authors.initials: Q
authors.lastname: Huang
authors.forename: Juan
authors.initials: J
authors.lastname: Zhou
authors.forename: Xiang-Chao
authors.initials: XC
authors.lastname: Wang
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.forename: Jin-Lin
authors.initials: JL
authors.lastname: Ma
authors.forename: Ning
authors.initials: N
authors.lastname: Tian
authors.forename: Gong-Jie
authors.initials: GJ
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000792:Angiography / Q000379:methods*; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D003287:Contrast Media; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009361:Neoplasm Invasiveness; D011379:Prognosis; D011856:Radiographic Image Enhancement / Q000379:methods; D011857:Radiographic Image Interpretation, Computer-Assisted / Q000379:methods; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D018511:Systems Integration; D036542:Tomography, Spiral Computed / Q000379:methods*
chemical_list: D003287:Contrast Media
keywords: X-ray computer; non-small cell lung cancer; progress of diseases; spiral CT scanning; targeted therapy